Beshair Alsaffar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beshair Alsaffar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Duncan Q. M. Craig
University of Bath
1 shared publication - James Benjamin Phillips
School of Pharmacy, UCL, 29-39 Brunswick Square, London WC1N 1AX, U.K.
1 shared publication - Lulwah Al-Bassam
UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
1 shared publication - Maryam Parhizkar
University College London
1 shared publication - Poppy O. Smith
UCL Centre for Nerve Engineering, Department of Pharmacology, UCL School of Pharmacy, University College London, London WC1N 1AX, UK
1 shared publication Tahera Ansari
University College London
1 shared publication
Latest Publications
- Open Access
- 21 May 2026
- Published by IOP Publishing in Biofabrication
- Vol. 18 (3)
Decellularization of porcine small-diameter vascular grafts: evaluation of a latrunculin B-based method and novel perfusion approach
Arteriovenous grafts are widely used for hemodialysis access, yet high failure rates remain a major clinical challenge. Decellularized blood vessels offer promising alternatives, but effective protocols must remove cellular and antigenic components while preserving extracellular matrix (ECM) integrity. This is particularly challenging in elastic arteries, where smooth muscle cells are anchored by dense actin filaments that are difficult to remove without ECM damage from harsh treatments. Here, we present a decellularization strategy based on actin-disrupting agents, specifically Latrunculin B, to facilitate removal of these dense cytoskeletal structures. The protocol integrates osmotic shock, high-ionic-strength salts, and Triton X-100 within a shortened processing time. Full-length porcine carotid arteries were decellularized using a dual-flow perfusion system, and five protocols were evaluated for removal of nuclear and immunogenic material, ECM preservation, mechanical properties, and cytocompatibility with human endothelial cells (HUVECs). All protocols substantially reduced nuclear material while preserving elastin, collagen, and mechanical integrity. Complete removal of immunogenic proteins was achieved with a final alkaline Triton X-100 wash (pH 8–14), highlighting the effectiveness of alkaline treatment in solubilizing membrane-bound antigens. All scaffolds supported HUVEC adhesion and formed a confluent endothelial monolayer within 8 days. Overall, integrating actin disruption via Latrunculin B with dual-salt–Triton processing, alkaline washing, and perfusion enhances decellularization efficiency, preserves ECM structure, reduces processing time and cost, and yields cytocompatible small-diameter vascular scaffolds with strong translational potential.
- 21 May 2026
- Published by IOP Publishing in Biofabrication
- Vol. 18 (3)
Open AccessDecellularization of porcine small-diameter vascular grafts: evaluation of a latrunculin B-based method and novel perfusion approach
Arteriovenous grafts are widely used for hemodialysis access, yet high failure rates remain a major clinical challenge. Decellularized blood vessels offer promising alternatives, but effective protocols must remove cellular and antigenic components while preserving extracellular matrix (ECM) integrity. This is particularly challenging in elastic arteries, where smooth muscle cells are anchored by dense actin filaments that are difficult to remove without ECM damage from harsh treatments. Here, we present a decellularization strategy based on actin-disrupting agents, specifically Latrunculin B, to facilitate removal of these dense cytoskeletal structures. The protocol integrates osmotic shock, high-ionic-strength salts, and Triton X-100 within a shortened processing time. Full-length porcine carotid arteries were decellularized using a dual-flow perfusion system, and five protocols were evaluated for removal of nuclear and immunogenic material, ECM preservation, mechanical properties, and cytocompatibility with human endothelial cells (HUVECs). All protocols substantially reduced nuclear material while preserving elastin, collagen, and mechanical integrity. Complete removal of immunogenic proteins was achieved with a final alkaline Triton X-100 wash (pH 8–14), highlighting the effectiveness of alkaline treatment in solubilizing membrane-bound antigens. All scaffolds supported HUVEC adhesion and formed a confluent endothelial monolayer within 8 days. Overall, integrating actin disruption via Latrunculin B with dual-salt–Triton processing, alkaline washing, and perfusion enhances decellularization efficiency, preserves ECM structure, reduces processing time and cost, and yields cytocompatible small-diameter vascular scaffolds with strong translational potential.